Showing papers in "Journal of Thoracic Oncology in 2015"

TL;DR: The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes from the 2004 WHO classification.

TL;DR: The 2015 WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart features the incorporation of many exciting new advances in thoracic tumor diagnosis and classification.

TL;DR: The results imply that EGFR-TKIs could not only directly inhibit tumor cell viability but also indirectly enhance antitumor immunity through the downregulation of PD-L1.

TL;DR: Current N descriptors adequately predict the prognosis and therefore should be maintained in the forthcoming staging system, and it is recommended that physicians record the number of metastatic lymph nodes and to further classify the N category using new descriptors, such as N1a, N1b, N2a,N2b, and N3, for further testing.

TL;DR: The 4th edition of the World Health Organization (WHO) Classification of thymic tumors has two aims: 1) to comprehensively list the established and new tumor entities and variants that are described in the new WHO Classification of Thymic epithelial tumors, germ cell tumors, lymphomas, dendritic cell and myeloid neoplasms, and soft-tissue tumors of the thymus and mediastinum; and 2) to highlight major differences in this classification that result from the progress that has been made since the 3rd edition in 2004 at

TL;DR: The presence of STAS is a significant risk factor of recurrence in small lung adenocarcinomas treated with limited resection and this findings support the proposal that STAS should formally be recognized as a pattern of invasion in lungAdenocARCinoma.

TL;DR: Multi-institutional molecular analysis across multiple platforms, sample types, and institutions can yield consistent results and novel clinicopathological observations in Lung Cancer Mutation Consortium patients.

TL;DR: The findings conclusively establish BAP1 as the most commonly mutated gene in MM, regardless of ethnic background or other clinical characteristics, according to genomic and immunohistochemical analyses.

TL;DR: Current data on the IHC biomarker aspects of studies using these drugs in non-small-cell lung cancer (NSCLC) and the challenges ahead are reviewed and the prospect of trying to harmonize and standardize testing for PD-L1 by IHC is raised, at least at a technical level.

TL;DR: Afatinib appears to penetrate into the CNS with concentrations high enough to have clinical effect on CNS metastases, and may be an effective treatment for heavily pretreated patients with EGFR-mutated or EGFR–TKI-sensitive NSCLC and CNS metastasis.

TL;DR: The expression of PD-1 and its ligands PD-L1 andPD-L2 is heterogeneous within KRAS-mutant NSCLC and suggests an inducible expression ofPD- L1 by smoking.

TL;DR: Ent rectinib demonstrated significant anti-tumor activity in a patient with NSCLC harboring an SQSTM1-NTRK1 gene rearrangement, indicating that entrectinib may be an effective therapy for tumors with NTRK gene rearrANGements, including those with central nervous system metastases.

TL;DR: Gefitinib and erlotinib are active in patients with G719X/L861Q/S768I mutations; however, less effective than in those with common mutations.

TL;DR: In this paper, the authors identified the mechanisms of acquired resistance to AZD9291 in EGFR T790M -mutant non-small-cell lung cancer (NSCLC) patients.

TL;DR: Wedge and segmental resections were shown to have significantly worse OS compared with lobectomy, and patients undergoing sublobar resection were more likely to have inadequate lymphadenectomy and positive margins.

TL;DR: All data on treatment options feasible for pulmonary LCNEC, both for localized and extensive disease are reviewed, with SCLC-like chemotherapy seems the best option of treatment, with a good response rate but a poor overall survival.

TL;DR: This is the first study showing a strong correlation between the EGFR SQI in the first days of treatment and clinical response with relevant implications for patient management and a standardized PCR test is feasible.

TL;DR: Sarcopenia as determined by CT could be used to predict prognosis in patients with SCLC and Optimum reference values to predict cancer-specific outcomes should be tailored by further studies.

TL;DR: In patients with SCLC, expression of PD-L1 is positively correlated with a LD stage, and is independently predictive of a favorable outcome, independently of other factors.

TL;DR: Alectinib is active in ALK-rearranged NSCLC patients with LM, including in patients previously treated with crizotinib and ceritinib, and three of four patients experienced significant clinical and radiographic improvements in LM upon treatment with alect inib.

TL;DR: The pretreatment NLR and PLR represented significant prognostic indicators of survival in patients treated for early-stage non–small-cell lung carcinoma with stereotactic radiation and the PLR may be used as a prognostic indicator for nonlocal failure after stereOTactic radiation for early–stage lung cancer.

TL;DR: A retrospective survey of records from NSCLC patients tested for EGFR mutations during 2011 is conducted in 11 Asian Pacific countries at 40 sites that routinely performed EGFR mutation testing during that period to provide a reference platform from which to improve the molecular diagnosis ofNSCLC, and EGFR mutant testing in particular, in Asia.

TL;DR: Next-generation sequencing was applied to a relatively large retrospective series of MPM using formalin-fixed, paraffin-embedded archival material and results indicate a complex mutational landscape with a higher number of genetic variations in the p53/DNA repair and phosphatidylinositol 3-kinase pathways, some of them with prognostic value.

TL;DR: The findings support the genetic heterogeneity of NSCLC in Latin America, confirming that the frequency of EGFR mutations is intermediate between that observed in the Asian and Caucasian populations.

TL;DR: EBUS-TBNA was superior to mediastinoscopy in terms of its diagnostic performance for mediastinal staging of cN1–3 NSCLC and should be the first-line procedure performed in patients withNSCLC.

TL;DR: Pem-Cb did not produce significantly better G4PFS compared with Pac+Cb+Bev, and both regimens were well tolerated, although, toxicity profiles differed.

TL;DR: These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma and further trials are warranted to study combination therapies and drug resistance mechanisms.

TL;DR: Treatment of LC with EGFR TKI, cytotoxic chemotherapy, or WBRT in selected patients is associated with prolong survival period, and these treatment options should be studied in patients with EG FR mutation-positive NSCLC and LC.

TL;DR: Pre-existing ILD was a significant risk factor for symptomatic and severe RP and Prescreening for ILD findings is important for determining the radiation pneumonitis risk when planning SBRT.